Nk521 cell therapy for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new immune cell treatment called NK521 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if this therapy can help shrink tumors, including in patients with liver cancer, ovarian cancer, or malignant ascites (fluid buildup in the belly with cancer cells).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed solid tumor, such as liver or ovarian cancer, that has not responded to at least one prior standard treatment.
- You have measurable tumors seen on CT or MRI scans.
- You are able to care for yourself (ECOG 0-2) and have a life expectancy of at least 3 months.
- You do not have untreated brain metastases, severe heart disease, or active infections like HIV or hepatitis.
- You have not had certain cancer treatments or blood products within the past few weeks, or cell therapy within the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new therapy that uses your own natural killer (NK) cells, modified to better fight cancer and injected directly into your abdomen. It's for people with advanced ovarian cancer who cannot have surgery or whose tumor cannot be fully removed.
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
This trial tests a new natural killer (NK) cell therapy, NK510, for people with advanced non-small cell lung cancer who have already tried immunotherapy and it stopped working. The goal is to see if NK510 is safe and can shrink tumors or slow the cancer's growth.
This trial tests a new natural killer (NK) cell therapy called NK510 for people with advanced gastric or colorectal cancer that has not responded to at least two prior treatments. The study aims to see if NK510 can help shrink tumors or slow the disease.
This early-stage trial tests NK521, a new immunotherapy infusion, for patients with advanced solid tumors (like liver, stomach, or colon cancer) that have spread and caused fluid buildup in the belly. The goal is to see if NK521 can help shrink tumors and improve survival when standard treatments have stopped working.
This trial tests an investigational natural killer (NK) cell therapy for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these immune cells can shrink tumors and are safe.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.